September 25, 2018
Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Data will be highlighted in an oral presentation at world’s largest meeting dedicated to lung… Read More
learn more
September 25, 2018
Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Data will be highlighted in an oral presentation at world’s largest meeting dedicated to lung… Read More
learn more
September 12, 2018
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan Zai Lab will support enrollment of Chinese patients to certain clinical trials investigating Tumor Treating Fields, intended to accelerate clinical trial enrollment Tumor… Read More
learn more
September 12, 2018
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan Zai Lab will support enrollment of Chinese patients to certain clinical trials investigating Tumor Treating Fields, intended to accelerate clinical trial enrollment Tumor… Read More
learn more
September 5, 2018
Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Results support the use of Tumor Treating Fields in first potential indication outside of the… Read More
learn more
September 5, 2018
Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Results support the use of Tumor Treating Fields in first potential indication outside of the… Read More
learn more
